# Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

> **NCT01599793** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 19 (actual)

## Conditions studied

- Bone Metastases
- Castrate-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** cabozantinib
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** magnetic resonance imaging

## Key facts

- **NCT ID:** NCT01599793
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01599793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01599793, "Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01599793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*